Company Of The Day: Pfizer
What?
Pfizer’s (NYSE:PFE) Covid-19 vaccine could be available to children from ages five to eleven as soon as the end of October, per a report from Reuters.
Why?
Relevant Articles
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
- Is Pfizer Stock Undervalued At $40?
Pfizer and its partner BioNTech could have sufficient data from clinical trials for the age group to file for emergency use authorization (EUA) by the end of this month.
So What?
Pfizer stock remains up by about 21% year-to-date, driven by soaring demand for the Covid-19 vaccine. A potential approval for children should expand the addressable market for the shot further.
See Our Complete Analysis For Pfizer
Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates and Featured Analyses